During the last session, Outlook Therapeutics Inc (NASDAQ:OTLK)’s traded shares were 1.3 million, with the beta value of the company hitting 0.60. At the end of the trading day, the stock’s price was $2.09, reflecting an intraday loss of -8.93% or -$0.21. The 52-week high for the OTLK share is $12.85, that puts it down -514.83 from that peak though still a striking 58.37% gain since the share price plummeted to a 52-week low of $0.87. The company’s market capitalization is $52.05M, and the average intraday trading volume over the past 10 days was 1.03 million shares, and the average trade volume was 2.00 million shares over the past three months.
Outlook Therapeutics Inc (OTLK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. OTLK has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.52.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Outlook Therapeutics Inc (OTLK) registered a -8.93% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.93% in intraday trading to $2.09, hitting a weekly high. The stock’s 5-day price performance is -3.24%, and it has moved by 49.29% in 30 days. Based on these gigs, the overall price performance for the year is -70.06%. The short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) is 4.13 million shares and it means that shorts have 1.26 day(s) to cover.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Statistics show that Outlook Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Outlook Therapeutics Inc (OTLK) shares have gone down -74.29% during the last six months, with a year-to-date growth rate more than the industry average at 43.61% against 16.50.
Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 702.6k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.45%. While earnings are projected to return 48.72% in 2025.
OTLK Dividends
Outlook Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Outlook Therapeutics Inc insiders own 35.58% of total outstanding shares while institutional holders control 35.63%, with the float percentage being 55.31%. ROSALIND ADVISORS, INC. is the largest shareholder of the company, while 94.0 institutions own stock in it. As of 2024-06-30, the company held over 0.45 million shares (or 3.1534% of all shares), a total value of $3.32 million in shares.
Also, the Mutual Funds coming in first place with the largest holdings of Outlook Therapeutics Inc (OTLK) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 442.51 shares. This amounts to just over 1.78 percent of the company’s overall shares, with a $0.92 million market value. The same data shows that the other fund manager holds slightly less at 369.41, or about 1.48% of the stock, which is worth about $0.77 million.
